Liraglutide (LRT) (AA 7-37) Peptide
-
- 抗原
- Liraglutide (LRT)
- 蛋白结构域
- AA 7-37
- 资源
- 合成
- Supplier Product No.
- 000-001-m40
- Supplier
- Rockland
- 原理
- Liraglutide (GLP 7-37,pal) peptide
- 纯度
- Greater than 95% specific peptide.
-
- 应用备注
-
Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay.
Application_Note: Liraglutide (GLP 7-37,pal) Control Peptide is suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
-
Reconstitution_Buffer: Restore with deionized water (or equivalent)
Reconstitution_Volume: 1.0 mL
- 浓度
- 1.0 mg/mL
- 储存液
- Without preservative
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
- 有效期
- 12 months
-
- 抗原
- Liraglutide (LRT)
- 背景
-
Synonyms: control peptide, blocking peptide, acylated glucagon-like peptide-1, diabetes research peptide, GLP-1 analogue
Background: Liraglutide is a human glucagon-like peptide-1 (GLP-1) agonist. GLP-1 (7-37) activates the GLP-1 cell-surface membrane-bound receptor in pancreatic beta cells. Liraglutide regulates insulin and glucagon secretions.
-
